#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Tosh Butt Email
EVP, COO . ChemoCentryx
How to contact Tosh Butt
Join and see Tosh's contact info for free!Current Roles
Employees:
78Revenue:
$34.3MAbout
ChemoCentryx, Inc. discovers, develops and commercializes novel small molecule medicines for autoimmune diseases, inflammatory disorders, cancer and infectious disease. Traficet-EN(TM), the company's orally active drug for inflammatory bowel disease, will enter clinical trials in 2003. Other products include an orally active development candidate for rheumatoid arthritis and multiple sclerosis, and emerging drug candidates for cancer and cardiopulmonary inflammation. Another drug, T487, resulted from a ChemoCentryx discovery program and is expected to enter Phase II clinical trials for psoriasis in 2003 with partner Tularik Inc. Leveraging its leadership in chemokine-based drug discovery, ChemoCentryx focuses on new classes of orally active small molecules to selectively inhibit activity of the chemokine system, the "master regulator" of immune response. Based in San Carlos, California, ChemoCentryx is privately held.ChemoCentryx Address
835 Industrial RdMountain View, CA
United States